Lycopene Skin Randomized Trial: What the Evidence Says

Quick Answer

Lycopene Skin Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Together, these mechanisms highlight lycopene's multifaceted bioactivity in maintaining health and reducing the risk of noncommunicable diseases. [Hajareh Haghighi Farid (2026); evidence level 3]
• While high-density lipoprotein (HDL) levels are not markedly increased, its functionality improves through enhanced antioxidant capacity and reverse cholesterol transport. [Hajareh Haghighi Farid (2026); evidence level 3]
• A diet rich in phytonutrients found in fruits and vegetables (FV) is critical for optimal health. [Jilcott Pitts Stephanie B. (2025); evidence level 4]
• Diets rich in carotenoids are linked with positive health outcomes, including reductions in the risk of cardiovascular disease and certain cancers. [Jilcott Pitts Stephanie B. (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For lycopene skin randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Hajareh Haghighi Farid (2026). Lycopene as Medicine: Unlocking the Therapeutic Power of a Bioactive Carotenoid. DOI: 10.1021/acsomega.6c01929. PMCID: PMC13191698. PMID: 42179603. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13191698/
• Jilcott Pitts Stephanie B. (2025). Daily intake of a lycopene-rich juice is associated with reductions in inflammatory markers but not increases in skin carotenoids in a pilot study among participants with obesity. DOI: 10.1186/s40795-025-01222-y. PMCID: PMC12838468. PMID: 41420244. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12838468/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.